DowDuPont Announces New Members for Future Board of Directors of DuPont

DowDuPont announced three additional members to the future board of directors of DuPont, currently the Specialty Products Division of DowDuPont. The new directors include Frank K. Clyburn, chief commercial officer at Merck & Co., Inc., Terrence R. Curtin, CEO of TE Connectivity, and Frederick M. Lowery, SVP and president, Life Sciences Solutions and Laboratory Products at Thermo Fisher Scientific Inc. With these additions, DuPont expects to have 12 members on its board, effective June 1, 2019.
 
“The new directors bring deep global expertise in electronics and pharmaceuticals, as well as manufacturing, further strengthening the overall board, which will work closely with the management team to oversee the successful execution of DuPont’s strategy and enhance value for shareholders,” Ed Breen, executive chairman-elect of DuPont and current chair and CEO of DowDuPont, said.
 
DowDuPont remains on track to separate the Agriculture Division (Corteva Agriscience) and Specialty Products Division (DuPont) on June 1, 2019.
 
In addition to Clyburn, Curtin,  and Lowery, DuPont’s future board of directors includes Breen; Ruby R. Chandy, former president of Industrial Division of Pall Corp.; Alexander M. Cutler, lead independent director of DowDuPont and former chairman and chief executive officer of Eaton; Marc Doyle, COO of the Specialty Products Division of DowDuPont and CEO-elect of DuPont; Eleuthère I. du Pont, former president and chief financial officer of Wawa and president of The Longwood Foundation; Rajiv L. Gupta, chairman of APTIV PLC (formerly Delphi Automotive PLC) and former chairman and CEO of Rohm & Haas; Luther C. Kissam, IV, chairman, president and CEO of Albemarle Corporation; Raymond J. Milchovich, former chairman and CEO of Foster Wheeler AG; and Steven Sterin, former EVP, CFO of Andeavor and former president of Andeavor Logistics.
 
Clyburn became CCO at Merck in 2019 and is responsible for operations and P&L across Merck’s human health commercial portfolio globally. He previously held various senior leadership positions within the company, most recently serving as president of Global Oncology from 2013 to 2018. He joined Merck in 2008 following eight years as VP of various business units at Sanofi-Aventis S.A. Earlier in his career, Mr. Clyburn served in a wide range of commercial roles of increasing responsibility at Hoechst Marion Roussel Inc. (now part of Sanofi) from 1994 to 2000. He started his career at Marion Merrell Dow Inc. from1987 to 1994.
 
Prior to assuming the role of CEO in 2017, Curtin served as TE’s President, where he was responsible for all of the company’s businesses and mergers and acquisition activities. He joined TE Connectivity in 2001 and has held various senior positions within the company, including as CFO. Prior to TE Connectivity, Mr. Curtin had positions of increasing responsibility at Arthur Andersen LLP from 1990 to 2001.
 
Lowery leads the Thermo Fisher’s BioProduction, Laboratory Products and Laboratory Chemicals businesses, as well as several functions within Life Sciences Solutions. Since joining Thermo Fisher in 2005, he has held a number of senior leadership positions across businesses. Prior to his time at Thermo Fisher, Lowery was with Maytag Corporation from 1999 to 2005. He began his career as an engineer at General Motors Company, where he worked from 1994 to 1999.